Fate Therapeutics Inc (NASDAQ:FATE) stock fell 6.86% (As on June 18, 11:15:55 AM UTC-4, Source: Google Finance) after Piper Sandler shifted its stance on the stock, raising the rating from Neutral to Overweight and increasing the price target to $6.00 from the previous $4.00. The biopharmaceutical company, known for its work in developing programmed cell therapies for cancer and immune disorders, has recently begun dosing the first patient with systemic lupus erythematosus (SLE) in a Phase I study of FT819 (CD19 CAR-IT).
Fate Therapeutics is also advancing its Phase I study of ADR-armed FT522 (CD19 CAR-INK) for patients with relapsed/refractory B-cell lymphoma. The study is exploring different dosing levels with and without preconditioning. Additionally, the company has plans to submit an Investigational New Drug (IND) application for FT522 in multiple autoimmune diseases by mid-2024.
Clinical results have shown that cancer patients undergoing treatment with FT819 or FT522 experienced effective B-cell depletion. This outcome is anticipated to be beneficial in achieving an immune reset in patients with autoimmune diseases. As of the end of the first quarter of 2024, Fate Therapeutics reported a cash position of $391 million.
The upgrade to Overweight reflects Piper Sandler’s positive outlook on the potential of FT819 and FT522 in the treatment of autoimmune diseases. With the company’s continued progress in its clinical studies and a robust financial standing, the increase in the price target to $6.00 from $4.00 signifies a renewed confidence in Fate Therapeutics’ strategic direction and therapeutic developments.
Meanwhile, Fate Therapeutics has experienced significant developments in both financial and clinical aspects. The biopharmaceutical company reported a net loss of $0.47 per share for the first quarter of 2024, closely aligning with the anticipated net loss of $0.46 per share. Its collaboration revenue for the quarter was reported at $1.9 million, nearly double the forecasted $1.0 million. In addition to the financial updates, Fate Therapeutics highlighted progress in its clinical programs. Notably, its FT819 CAR T-cell therapy showed promise for B-cell-mediated autoimmune diseases, and FT522, a CAR NK cell therapy, demonstrated efficacy in B-cell lymphoma patients. The company also initiated a Phase I study for FT825 in solid tumors.
On the other hand, Cash, cash equivalents and investments as of March 31, 2024 were $391.1 million, which includes net proceeds from the closing of the Company’s approximately $80 million underwritten offering of common stock at $5.50 per share and approximately $20 million concurrent private placement of pre-funded warrants at $5.499 per pre-funded warrant in the first quarter of 2024.